Unknown

Dataset Information

0

Antihypertensive drug use and prostate cancer-specific mortality in Finnish men.


ABSTRACT: The aim of this study was to investigate pre- and post-diagnostic use of antihypertensive drugs on prostate cancer (PCa)-specific survival and the initiation of androgen deprivation therapy (ADT). The cohort investigated 8,253 PCa patients with 837 PCa-specific deaths during the median follow-up of 7.6 years after diagnosis. Information on drug use, cancer incidence, clinical features of PCa, and causes of death was collected from Finnish registries. Hazard ratios with 95% confidence intervals were calculated using Cox regression with antihypertensive drug use as a time-dependent variable. Separate analyses were performed on PCa survival related to pre- and post-diagnostic use of drugs and on the initiation of ADT. Antihypertensive drug use overall was associated with an increased risk of PCa-specific death (Pre-PCa: 1.21 (1.04-1.4), Post-PCa: 1.2 (1.02-1.41)). With respect to the separate drug groups, angiotensin II type 1 receptor (ATr) blockers, were associated with improved survival (Post-PCa: 0.81 (0.67-0.99)) and diuretics with an increased risk (Post-PCa: 1.25 (1.05-1.49)). The risk of ADT initiation was slightly higher among antihypertensive drug users as compared to non-users. In conclusion, this study supports anti-cancer effect of ATr blockers on PCa prognosis and this should be investigated further in controlled clinical trials.

SUBMITTER: Siltari A 

PROVIDER: S-EPMC7323967 | BioStudies | 2020-01-01

REPOSITORIES: biostudies

Similar Datasets

2014-01-01 | S-EPMC4301544 | BioStudies
2020-01-01 | S-EPMC7502080 | BioStudies
2009-01-01 | S-EPMC2788785 | BioStudies
2019-01-01 | S-EPMC6617729 | BioStudies
2020-01-01 | S-EPMC7464259 | BioStudies
2020-01-01 | S-EPMC7486443 | BioStudies
2011-01-01 | S-EPMC3034269 | BioStudies
2019-01-01 | S-EPMC6752995 | BioStudies
1000-01-01 | S-EPMC4974886 | BioStudies
2020-01-01 | S-EPMC7092991 | BioStudies